18:24:11 Europe / Stockholm



2025-01-15 Kvartalsrapport 2025-Q1
2025-01-15 Årsstämma 2025
2024-10-09 Bokslutskommuniké 2024
2024-07-10 Kvartalsrapport 2024-Q3
2024-04-10 Kvartalsrapport 2024-Q2
2024-01-11 X-dag ordinarie utdelning NEWBRY 0.00 SEK
2024-01-10 Årsstämma 2024
2024-01-10 Kvartalsrapport 2024-Q1
2023-10-11 Bokslutskommuniké 2023
2023-07-14 Kvartalsrapport 2023-Q3
2023-04-12 Kvartalsrapport 2023-Q2
2023-01-12 X-dag ordinarie utdelning NEWBRY 0.00 SEK
2023-01-11 Kvartalsrapport 2023-Q1
2023-01-11 Årsstämma 2023
2022-10-13 Bokslutskommuniké 2022
2022-07-06 Kvartalsrapport 2022-Q3
2022-04-13 Kvartalsrapport 2022-Q2


ListaFirst North Stockholm
IndustriLäkemedel & Handel
Newbury Pharmaceuticals är verksamt inom läkemedelsbranschen. Bolaget utvecklar en pipeline av egenutvecklade och licensierade produkter med fokus på specialläkemedel inom områden som onkologi, sällsynta sjukdomar och neurologi. Bolaget bedriver sin verksamhet inom den skandinaviska marknaden. Newbury Pharmaceuticals grundades 2020 och har sitt huvudkontor i Lund.
2022-01-31 16:45:00

Due to the planned listing on Nasdaq First North Growth Market, Newbury Pharmaceuticals AB (publ) ("Newbury" or "the Company") has today prepared a supplementary document which is available on Newbury's website, www.newburypharma.com.

The supplementary document contains certain information regarding the capitalization structure, net indebtedness and ownership structure related to Newbury and reflects the Company after the new share issue (the "Offer"). The supplementary document also contains some additional information which means that Newbury meets the requirements set out in the Nasdaq First North Rulebook.

The supplementary document shall be read as a supplement to the prospectus that the Company published on January 11, 2022, in connection with the Offer. The supplementary document is not a prospectus, has not been reviewed or approved by any supervisory authority and does not contain any offer of shares or other financial instruments.

Newbury has previously received a preliminary and conditional notice from Nasdaq that the Company meets the listing requirements, with customary conditions and reservations. The first day of trading on Nasdaq First North Growth Market is scheduled for February 4, 2022, under the short name NEWBURY.